We are live on ! Find out more
CS

Candriam SCA Portfolio holdings

AUM $19.3B
1-Year Est. Return 39.18%
This Fund
S&P 500
This Quarter Est. Return
+29.29%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$9.47B
AUM Growth
+$451M
Cap. Flow
+$1.13B
Cap. Flow %
11.96%
Top 10 Hldgs %
21.59%
Holding
903
New
107
Increased
255
Reduced
393
Closed
103

Top Buys

Rank Stock Value
1
BPMC
Blueprint Medicines
BPMC
+$51.9M
2
MRK icon
Merck
MRK
+$50.9M
3
DHR icon
Danaher
DHR
+$45.3M
4
TMO icon
Thermo Fisher Scientific
TMO
+$37.8M
5
JD icon
JD.com
JD
+$37.7M

Top Sells

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$103M
2
BABA icon
Alibaba
BABA
+$98.6M
3
CRM icon
Salesforce
CRM
+$62.5M
4
BMY icon
Bristol-Myers Squibb
BMY
+$59.4M
5
VRTX icon
Vertex Pharmaceuticals
VRTX
+$48.6M

Sector Composition

Rank Sector Weight
1 Healthcare 34.61%
2 Technology 20.94%
3 Consumer Discretionary 8.9%
4 Financials 8.59%
5 Communication Services 7.45%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AFYA icon
176
Afya
AFYA
$1.3B
$12.6M 0.13%
539,000
+197,500
+58% +$4.06M
BHVN
177
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$12.6M 0.13%
172,799
-16,000
-8% -$851K
CPB icon
178
Campbell Soup
CPB
$6.67B
$12.6M 0.13%
254,218
+104,480
+70% +$5.19M
MRTX
179
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$12.6M 0.13%
110,061
+10,733
+11% +$1.04M
MCD icon
180
McDonald's
MCD
$192B
$12.6M 0.13%
68,056
-20,181
-23% -$3.7M
CHTR icon
181
Charter Communications
CHTR
$15.7B
$12.6M 0.13%
24,607
+13,006
+112% +$6.6M
ZYME icon
182
Zymeworks
ZYME
$1.69B
$12.4M 0.13%
344,484
+112,215
+48% +$4.13M
ARVN icon
183
Arvinas
ARVN
$530M
$12.2M 0.13%
364,285
+91,462
+34% +$3.88M
WMS icon
184
Advanced Drainage Systems
WMS
$11B
$12.2M 0.13%
247,015
+117,262
+90% +$4.82M
CI icon
185
Cigna
CI
$77B
$12.2M 0.13%
64,949
-7,110
-10% -$1.35M
BDX icon
186
Becton Dickinson
BDX
$43.8B
$12M 0.13%
51,265
-13,523
-21% -$3.26M
CHRS icon
187
Coherus Oncology
CHRS
$225M
$11.9M 0.13%
666,372
+328,577
+97% +$5.56M
CNST
188
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$11.9M 0.13%
394,652
+270,868
+219% +$9.76M
HOLI
189
DELISTED
Hollsys Automation Technologies INTERNATIONAL, LTD. COMMON (British Virgin Island)
HOLI
$11.9M 0.13%
891,448
+40,929
+5% +$556K
CHD icon
190
Church & Dwight Co
CHD
$23.4B
$11.7M 0.12%
151,666
+65,283
+76% +$4.75M
CEVA icon
191
CEVA Inc
CEVA
$980M
$11.7M 0.12%
311,894
+14,460
+5% +$464K
TJX icon
192
TJX Companies
TJX
$173B
$11.7M 0.12%
230,717
-238,824
-51% -$12M
MDGL icon
193
Madrigal Pharmaceuticals
MDGL
$12.7B
$11.6M 0.12%
102,584
+61,634
+151% +$6.06M
ACAD icon
194
Acadia Pharmaceuticals
ACAD
$4.35B
$11.6M 0.12%
239,000
+159,000
+199% +$7.63M
FTNT icon
195
Fortinet
FTNT
$112B
$11.5M 0.12%
419,915
-248,085
-37% -$6.23M
HDB icon
196
HDFC Bank
HDB
$119B
$11.5M 0.12%
506,662
+474,662
+1,483% +$9.74M
AMBA icon
197
Ambarella
AMBA
$2.99B
$11.3M 0.12%
247,613
+73,290
+42% +$3.78M
CVS icon
198
CVS Health
CVS
$137B
$11.3M 0.12%
173,377
+4,959
+3% +$312K
FOLD
199
DELISTED
Amicus Therapeutics
FOLD
$11.2M 0.12%
741,588
-187,912
-20% -$2.29M
GIS icon
200
General Mills
GIS
$19.5B
$11.2M 0.12%
181,135
+53,276
+42% +$3.21M
6 7
8
9 10

Similar funds

PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
A
AustralianSuper Melbourne, Australia $19.2B AUM 31.95% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $19.4B AUM 16.7% 1-Year Est. Return
LF
Lansforsakringar Fondforvaltning Stockholm, Sweden $19.1B AUM 26.9% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return
SOMRS
State of Michigan Retirement System Lansing, Michigan $18.9B AUM 27.96% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $18.9B AUM 18.9% 1-Year Est. Return
MIM
MetLife Investment Management Whippany, New Jersey $19.6B AUM 32.64% 1-Year Est. Return

Candriam SCA's Q2 2020 Portfolio in Review

As of Q2 2020, Candriam SCA held 903 positions worth $9.47B, up 5% from $9.02B the previous quarter. Its ten largest holdings account for 22% of the portfolio.

Candriam SCA deployed $1.13B of net new capital in Q2 2020, opening 107 new positions and adding to 255 existing holdings. Its largest new stake was JD.com: 744,410 shares worth $44.8M.

By sector, the portfolio is most concentrated in Healthcare at 35% of assets, up from 31% a quarter earlier, followed by Technology and Consumer Discretionary.

On the sell side, the largest reduction was Regeneron Pharmaceuticals, an estimated $103M trimmed.

  • Candriam SCA's largest Q2 2020 buy was JD.com: 744,410 shares worth $44.8M.
  • Candriam SCA added most to Blueprint Medicines in Q2 2020, an estimated $51.9M increase.
  • Candriam SCA's biggest Q2 2020 reduction was Regeneron Pharmaceuticals, cutting an estimated $103M.
  • Candriam SCA fully exited Salesforce in Q2 2020, selling an estimated $62.5M.
  • Candriam SCA's ten largest holdings make up 22% of its $9.47B portfolio in Q2 2020.
  • Candriam SCA opened 107 new positions and closed 103 in Q2 2020.
  • Candriam SCA's portfolio value rose 5% quarter-over-quarter to $9.47B.

Based on Candriam SCA's 13F filing for Q2 2020, filed 23 Jul 2020.